| Ident. | Authors (with country if any) | Title |
|---|
| 000B27 (2005) |
Nicolas Simon [France] ; Joëlle Micallef [France] ; Jean-Charles Reynier [France] ; Monique Lesourd [France] ; Tatiana Witjas [France] ; André Alicherif [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] | End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study |
| 000B38 (2005) |
Frédéric Libert [France] ; Francois Coudore [France] ; Damien Richard [France] ; Franck Durif [France] ; Alain Eschalier [France] | Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine |
| 000C13 (2004) |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew J. Lees [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study |
| 000D73 (2003) |
Asteria Luzardo-Alvarez [Espagne] ; M. Begona Delgado-Charro [France] ; José Blanco-Mendez [Espagne] | In vivo lontophoretic administration of ropinirole hydrochloride |
| 000D84 (2003) |
Charles Crevoisier [Suisse] ; Patricia Zerr [France] ; Francoise Calvi-Gries [France] ; Turid Nilsen [Norvège] | Effects of food on the pharmacokinetics of levodopa in a dual-release formulation |
| 000D95 (2003) |
C. Crevoisier [Suisse] ; A. Monreal [France] ; B. Metzger [France] ; T. Nilsen [Norvège] | Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers |
| 000E32 (2002) |
J. L. Montastruc [France] ; O. Rascol [France] | Propriétés pharmacodynamiques des agonistes dopaminergiques ? Quelle transférabilité en pratique clinique dans le traitement de la maladie de Parkinson ? |
| 000F30 (2002) |
H. E. Junginger [Pays-Bas] | Iontophoretic delivery of apomorphine: from in-vitro modelling to the Parkinson patient |
| 000F34 (2002) |
A. Angles [France] ; H. Bagheri [France] ; S. Saivin [France] ; J. L. Montastruc [France] | Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease |
| 000F66 (2002) |
Bernard Bruguerolle [France] ; Nicolas Simon [France] | Biologic rhythms and Parkinson's disease: A chronopharmacologic approach to considering fluctuations in function |
| 001172 (2000) |
L. A. Smith [Royaume-Uni] ; M. G. Jackson [Royaume-Uni] ; C. Bonhomme [France] ; C. Chezaubernard [France] ; K. B. Pearce [Royaume-Uni] ; P. Jenner [Royaume-Uni] | Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset |
| 001190 (2000) |
Patrice Mayer [France] ; Pascale Brunel [France] ; Céline Chaplain [France] ; Christel Piedecoq [France] ; Francis Calmel [France] ; Philippe Schambel [France] ; Philippe Chopin [France] ; Thierry Wurch [France] ; Petrus J. Pauwels [France] ; Marc Marien [France] ; Jean-Louis Vidaluc [France] ; Thierry Imbert [France] | New substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with α2-Adrenoceptor antagonist activity |
| 001209 (2000) |
Frédéric Dolle [France] ; Michel Bottlaender [France] ; Stéphane Demphel [France] ; Patrick Emond [France] ; Chantal Fuseau [France] ; Christine Coulon [France] ; Michele Ottaviani [France] ; Héric Valette [France] ; Christian Loc'H [France] ; Christer Halldin [Suède] ; Laurent Mauclaire [France] ; Denis Guilloteau [France] ; Bernard Maziere [France] ; Christian Crouzel [France] | Highly efficient synthesis of [11C]PE2I, a selective radioligand for the quantification of the dopamine transporter using PET |
| 001329 (1999) |
C. Thalamas [France] ; A. Taylor [Royaume-Uni] ; C. Brefel-Courbon [France] ; S. Eagle [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; O. Rascol [France] | Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease |
| 001336 (1999) |
H. Valette [France] ; M. Bottlaender [France] ; F. Dolle [France] ; I. Guenther [France] ; C. Fuseau [France] ; C. Coulon [France] ; M. Ottaviani [France] ; C. Crouzel [France] | Imaging central nicotinic acetylcholine receptors in baboons with [18F]fluoro-A-85380 |
| 001377 (1998-04) |
| Synthèse de radioligands marqués au brome-76 et au carbone-11 pour l'étude des récepteurs N-Méthyl-D-Aspartate par Tomographie d'Emission de Positons |
| 001454 (1998) |
C. Brefel [France] ; C. Thalamas [France] ; S. Rayet [France] ; A. Lopez-Gil [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; S. Bullman [Royaume-Uni] ; D. R. Citerone [Royaume-Uni] ; A. C. Taylor [Royaume-Uni] ; J. L. Montastruc [France] ; O. Rascol [France] | Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients |
| 001502 (1997) |
P. Pollak [France] | Mécanismes et traitements de la maladie de Parkinson : Mouvements anormaux |
| 001537 (1997) |
A. Daniele [Italie] ; A. Albanese [France] ; G. Gainotti [France] ; B. Gregori [France] ; P. Bartolomeo [France] | Zolpidem in Parkinson's disease |
| 001790 (1994) |
J. Dow [France] ; F. Piriou ; E. Wolf [France] ; B. D. Dulery [France] ; K. D. Haegele | Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans |
| 001867 (1993) |
F. Durif [France] ; M. Paire [France] ; D. Deffond [France] ; A. Eschalier [France] ; G. Dordain [France] ; M. Tournilhac [France] ; J. Lavarenne [France] | Relation between clinical efficacy and pharmacokinetic parameters after sublingual apomorphine in Parkinson's disease |
